Management of Comorbidities in Chronic Heart Failure CLINICAL STATEMENTS AND GUIDELINES 242. FDA approves lorcaserin for the treatment of obesity. 2012. http:// www.theheart.org/article/1420361.do. Accessed July 2, 2012. 243. Ramani GV, McCloskey C, Ramanathan RC, Mathier MA. Safety and efficacy of bariatric surgery in morbidly obese patients with severe systolic heart failure. Clin Cardiol. 2008;31:516 520. doi: 10.1002/clc.20315. 244. Ristow B, Rabkin J, Haeusslein E. Improvement in dilated cardio- myopathy after bariatric surgery. J Card Fail. 2008;14:198 202. doi: 10.1016/j.cardfail.2007.12.006. 245. FDA approves weight-management drug Qsymia [news re- lease]. Bethesda, MD: US Food and Drug Administration. http:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm312468.htm. Accessed July 12, 2012. 246. Beck-da-Silva L, Higginson L, Fraser M, Williams K, Haddad H. Effect of Orlistat in obese patients with heart failure: a pilot study. Congest Heart Fail. 2005;11:118 123. 247. Weber MA, Neutel JM, Smith DH. Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. J Am Coll Cardiol. 2001;37:169 174. 248. Kardassis D, Bech-Hanssen O, Sch nander M, Sj str m L, Petzold M, Karason K. Impact of body composition, fat distribution and sustained weight loss on cardiac function in obesity. Int J Cardiol. 2012;159:128 133. doi: 10.1016/j.ijcard.2011.02.036. 249. Riegel B, Moser DK, Anker SD, Appel LJ, Dunbar SB, Grady KL, Gurvitz MZ, Havranek EP, Lee CS, Lindenfeld J, Peterson PN, Pressler SJ, Schocken DD, Whellan DJ; on behalf of the American Heart Association Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Nutrition, Physical Activity, and Metabolism, and Interdisciplinary Council on Quality of Care and Outcomes Research. State of the science: promoting self- care in persons with heart failure: a scientific statement from the American Heart Association. Circulation. 2009;120:1141 1163. doi: 10.1161/CIRCULATIONAHA.109.192628. 250. 